人类 ангиотензин转化酶-lisinopril复合物的晶体结构
Ramanathan Natesh1, Sylva L U Schwager, Edward D Sturrock
1Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath BA2 7AY, UK.
Nature
|January 24, 2003
概括
人类血管酶转化酶 (ACE) 的第一个X射线结构显示,它与碳氧酶A不同. 这一发现使得设计出新的,针对心血管疾病的域选择性ACE抑制剂成为可能.
科学领域:
- 生物化学 生物化学
- 结构生物学 结构生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- ангиотензин转化酶 (ACE) 通过产生 ангиотензин II 调节心血管功能.
- ACE 抑制剂是高血压和心力衰竭的关键治疗方法.
- 现有的ACE抑制剂是在不了解人类ACE结构的情况下设计的.
研究的目的:
- 为了确定人类丸ACE的X射线结构.
- 为了可视化人类ACE的复杂性,使用抑制剂lisinopril.
- 为设计新型ACE抑制剂提供见解.
主要方法:
- 使用X射线晶体学来确定人类丸ACE的结构.
- 该结构的分辨率为2.0 Å分辨率.
- 分析了含有利西诺普里尔的复合物.
主要成果:
- 人类ACE的三维结构得到了阐明.
- 在结构上,ACE与神经酶和Pyrococcus furiosus carboxypeptidase相似,而不是carboxypeptidase A.
- 确定了ACE与lysinopril复合的结构.
结论:
- 人类的ACE结构与碳氧酸酶A不同.
- 确定的结构为设计域选择性ACE抑制剂提供了基础.
- 可能可以实现ACE抑制剂的新药理学概况.
相关概念视频
Kidney Structure
The kidneys are two large bean-shaped organs located in the upper abdomen. They filter the blood several times a day to remove toxins and rebalance water and electrolytes of the circulatory system via the renal veins. The kidneys receive blood directly from the heart via the renal arteries. These arteries enter the kidney at the hilum, the concave surface of the bean, where they branch and divide into smaller vessels and capillaries.
Structure of Amines
The hybridized nitrogen atom in amines possesses a lone pair of electrons and is bound to three substituents with a bond angle of around 108°, which is less than the tetrahedral angle of 109.5°. However, the C–N–H bond angle is slightly larger at 112°, with a carbon–nitrogen bond length of 147 pm. This carbon–nitrogen bond length of of amines is longer than the carbon–oxygen bond of alcohols (143 pm) but shorter than alkanes’ carbon–carbon bond (154 pm). These aspects are illustrated in Figure...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...


